Study of a Short Course of Neoadjuvant Gleevec (Imatinib Mesylate) in Dermatofibrosarcoma Protuberans
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Imatinib (Primary)
- Indications Dermatofibrosarcoma
- Focus Therapeutic Use
- 28 Mar 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 28 Mar 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 28 Mar 2012 Actual end date (Sep 2009) added as reported by ClinicalTrials.gov.